{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytopenias&page=15", "query": { "condition": "Cytopenias", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 575, "total_pages": 58, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytopenias&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cytopenias&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:45:08.419Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01688011", "title": "Connect® Myeloid Disease Registry", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Myelofibrosis", "Myelodysplastic Syndromes", "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2013, "start_date": "2013-12-12", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 155, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688011" }, { "nct_id": "NCT06721013", "title": "A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Immune Thrombocytopenia (ITP)" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2025-07-30", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 10, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06721013" }, { "nct_id": "NCT02775383", "title": "The National Myelodysplastic Syndromes (MDS) Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Therapeutic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2115, "start_date": "2016-06-13", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 280, "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 213 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02775383" }, { "nct_id": "NCT00903422", "title": "Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2009-05-14", "completion_date": "2013-12-05", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903422" }, { "nct_id": "NCT02948283", "title": "Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia", "Fatigue", "Fever", "Lymphadenopathy", "Lymphocytosis", "Night Sweats", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Plasma Cell Myeloma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Plasma Cell Myeloma", "Splenomegaly", "Thrombocytopenia", "Weight Loss" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Quality-of-Life", "type": "OTHER" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-09-05", "completion_date": "2017-12-01", "has_results": false, "last_update_posted_date": "2021-02-12", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948283" }, { "nct_id": "NCT06999954", "title": "Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Shwachman-Diamond Syndrome", "SDS", "IBMF", "Congenital Neutropenia", "Heme Malignancy", "Shwachman Syndrome", "Inherited Bone Marrow Failure", "Exocrine Pancreatic Insufficiency", "WHIM", "ELANE", "SBDS Gene Mutation", "EFL1 Gene Mutation", "DNAJC21 Gene Mutation", "SRP54 Gene Mutation", "Inherited Cancer Syndrome", "Inherited Cancer-Predisposing Syndrome", "Neutropenia, Severe Chronic", "Neutropenia Other", "Neutropenia Chronic Benign", "Ribosome Alteration", "Ribosomopathy", "Immune Deficiency", "Inherited BMF Syndrome", "Inherited Immunodeficiency Diseases", "Cognitive Delay, Mild", "Myelodysplastic Syndromes", "Pancytopenia" ], "interventions": [], "intervention_types": [], "sponsor": "Shwachman-Diamond Syndrome Alliance Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 8000, "start_date": "2024-02-07", "completion_date": "2088-12", "has_results": false, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 1, "location_summary": "Woburn, Massachusetts", "locations": [ { "city": "Woburn", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06999954" }, { "nct_id": "NCT06566742", "title": "A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Olutasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-12-10", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 2, "location_summary": "Miami, Florida • Houston, Texas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06566742" }, { "nct_id": "NCT05855083", "title": "Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombotic Microangiopathies", "Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "Biological: narsoplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Omeros Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "28 Days to 17 Years" }, "enrollment_count": 18, "start_date": "2023-05-01", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-03-25", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 8, "location_summary": "San Diego, California • Gainesville, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05855083" }, { "nct_id": "NCT01891994", "title": "Extended Dosing With Eltrombopag for Severe Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia (SAA)" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "2 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2013-06-28", "completion_date": "2022-08-24", "has_results": true, "last_update_posted_date": "2023-04-25", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01891994" }, { "nct_id": "NCT00002302", "title": "The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Cytopenias" ], "interventions": [ { "name": "Epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ortho Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-17T09:45:08.419Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Raritan, New Jersey", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Raritan", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002302" } ] }